Esperion Therapeutics (ESPR) posts updated corporate presentation for investors

Rhea-AI Filing Summary

Esperion Therapeutics, Inc. filed a current report to note that on October 7, 2025 it posted an updated corporate presentation on its investor relations website. The same presentation, dated October 2025, is also provided as Exhibit 99.1 so investors can review the materials directly through the SEC system.

The filing does not introduce new financial statements or disclose specific transaction details. Instead, it formally records that the latest corporate overview and investor slide deck are now publicly available, helping ensure all market participants have equal access to the company’s updated messaging.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001434868 0001434868 2025-10-07 2025-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 7, 2025

Esperion Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-35986		26-1870780
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

3891 Ranchero Drive, Suite 150
Ann Arbor, MI

(Address of principal executive offices)

48108

(Zip Code)

Registrant’s telephone number, including area code: (734) 887-3903

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ESPR		NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company   ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ¨

Item 8.01. Other Events.

On October 7, 2025, Esperion Therapeutics, Inc. (the “Company”) posted an updated corporate presentation to its website at https://www.esperion.com/investors-media. A copy of the updated corporate presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Reference to the Company’s website is for inactive textual reference only and the content of the website should not be deemed incorporated by reference into this Current Report on Form 8-K

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation dated October 2025.
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 7, 2025	Esperion Therapeutics, Inc.
	By:	/s/ Sheldon L. Koenig
		Sheldon L. Koenig
		President and Chief Executive Officer

FAQ

What did Esperion Therapeutics (ESPR) disclose in this Form 8-K?

Esperion Therapeutics disclosed that it posted an updated corporate presentation on its website and furnished the same presentation as Exhibit 99.1. This filing mainly serves to make the investor materials publicly accessible through the SEC system.

Where can investors find Esperion Therapeutics’ updated corporate presentation?

Investors can find the updated corporate presentation on Esperion Therapeutics’ investor relations website and as Exhibit 99.1 to this Form 8-K. The website reference is described as inactive textual reference, with the exhibit serving as the formal SEC copy.

What is included as Exhibit 99.1 in Esperion Therapeutics’ 8-K?

Exhibit 99.1 is a corporate presentation dated October 2025. It represents Esperion Therapeutics’ updated investor slide deck, which the company has posted on its website and furnished with the Form 8-K for broad public access.

Does this Esperion Therapeutics 8-K include new financial statements?

This Form 8-K does not attach new financial statements. It lists only exhibits, including the October 2025 corporate presentation as Exhibit 99.1 and an Inline XBRL cover page as Exhibit 104, focusing on updated investor materials.

Why did Esperion Therapeutics file this 8-K about its corporate presentation?

Esperion filed this 8-K to formally note that it posted an updated corporate presentation and to furnish it as Exhibit 99.1. This ensures the investor materials are part of the public SEC record and available to all market participants equally.